Last reviewed · How we verify
TS-143
At a glance
| Generic name | TS-143 |
|---|---|
| Sponsor | Taisho Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration) (PHASE1)
- Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration) (PHASE1)
- Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients with Chronic Kidney Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TS-143 CI brief — competitive landscape report
- TS-143 updates RSS · CI watch RSS
- Taisho Pharmaceutical Co., Ltd. portfolio CI